Hildur Helgadottir

18PUBLICATIONS
56CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsMechanobiologyApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Predictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (18)

|Apr 24, 2026
The role of radiotherapy in patients with advanced melanoma failing targeted therapy.

|Feb 19, 2026
SWE-NEO: Swedish NEO-adjuvant trial comparing anti-PD-1 monotherapy to combined anti-CTLA-4/anti-PD-1 blockade in resectable stage III melanoma: study protocol for a phase III open-label multi-centre trial.

Hildur Helgadottir, Ana Carneiro, Francesca Portelli

|Feb 03, 2026
Eribulin-induced resolution of high-risk basal cell carcinoma: implications for microtubule-targeting agents in BCC management: a case report.

Jan Lapins, Niki Radros, Karina Schultz

|Dec 07, 2025
Evaluation of the flipped dose NIVO3+IPI1 in patients with advanced unresectable melanoma.

Karl Björkström, Cissi Liu, Anna Fager

|Sep 10, 2025
Germline MC1R Variant Status and Efficacy of Immune Checkpoint Inhibitors in Patients With Advanced Melanoma.

Muyi Yang, Suzanne Egyhazi Brage, Jan Lapins

|Aug 25, 2025
POT1 genetic testing in melanoma-prone families in Sweden: germline variant prevalence and tumor spectrum in identified carriers.

Konstantinos Papadakis, Francesca Portelli, Karina Schultz

Pageof 3

Frequent Collaborators

5 joint publications

Lars Ny

5 joint publications

Jan Lapins

3 joint publications

Roger Olofsson Bagge

2 joint publications

Amy Hutchinson